- 2, 4-diaminopyrimidine compound containing phenol fragment, preparation method, pharmaceutical compositions and use thereof
-
The invention discloses a 2, 4-diaminopyrimidine compound containing phenol fragment with a general formula I shown in the specification, pharmaceutically acceptable salts or pharmaceutically acceptable solvates, a preparation method thereof, pharmaceutical compositions containing the compounds, and use of the compounds in preparation of drugs for preventing or treating anaplastic lymphoma kinaserelated abnormal cell proliferation, morphological changes, hyperkinesia and other associated diseases in organisms, and angiogenesis or cancerometastasis associated diseases, especially use in drugsfor treating or preventing tumor growth and metastasis.
- -
-
Paragraph 0145; 0148; 0149
(2018/04/02)
-
- Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors
-
Two series of thienopyrimidine derivatives (10a-k, 16a-j) bearing chromone moiety were designed and synthesized. All the compounds were evaluated for inhibitory activity against mTOR kinase at a concentration of 10uM. Four selected compounds were further evaluated for the IC50 values against mTOR kinase, PI3Kα kinase and two cancer cell lines. Some of the target compounds exhibited moderate to excellent mTOR/PI3Kα kinase inhibitory activity and cytotoxicity. The most promising compound 16i showed good inhibitory activity against mTOR/PI3Kα kinase and good antitumor potency for H460 and PC-3 cell lines with IC50 values of 0.16 ± 0.03 μM, 2.35 ± 0.19 μM, 1.20 ± 0.23 μM and 0.85 ± 0.04 μM, which were 8.6, >5, 7.9 and 19.1 times more active than compound I (1.37 ± 0.07 μM, >10 μM, 9.52 ± 0.29 μM, 16.27 ± 0.54 μM), respectively. Structure-activity relationships (SARs) and docking studies indicated that the chromone moiety is necessary for the potent antitumor activity and cytotoxicity of these compounds. Substitution of the chromone moiety at the 6-position has a significant impact to the inhibitory activity, in particular a carboxylic acid group, produced the best potency.
- Zhu, Wufu,Chen, Chen,Sun, Chengyu,Xu, Shan,Wu, Chunjiang,Lei, Fei,Xia, Hui,Tu, Qidong,Zheng, Pengwu
-
-
- Design and syntheses of novel N′-((4-oxo-4H-chromen-3-yl)methylene) benzohydrazide as inhibitors of cyanobacterial fructose-1,6-/sedoheptulose-1,7- bisphosphatase
-
Cyanobacterial fructose-1,6-/sedoheptulose-1,7-bisphoshatase (Cy-FBP/SBPase) is an important target enzyme for finding inhibitors to solve harmful algal bloom (HAB). In this study, as potential inhibitors of Cy-FBP/SBPase, a series of novel chromone-connecting benzohydrazone compounds (Novel N′-((4-oxo-4H-chromen-3-yl)methylene)benzohydrazide) were designed and synthesized. Their inhibitory activities against Cy-FBP/SBPase were further examined in vitro. Some of these compounds, such as f6-f8, f11, f12 and f16, exhibit higher inhibitory activities (IC50 = 11.2-16.1 μM), especially, the compound f7 was identified as the most potent inhibitor with IC50 value of 11.2 μM. The probable binding-mode of compound f7 was further analyzed carefully by molecular docking methods. These results indicate that compound f7 could be used as a lead compound for further optimization and might have potential to be developed as a new algicide.
- Tu, Qi-Dong,Li, Ding,Sun, Yao,Han, Xin-Ya,Yi, Fan,Sha, Yibamu,Ren, Yan-Liang,Ding, Ming-Wu,Feng, Ling-Ling,Wan, Jian
-
p. 2826 - 2831
(2013/06/27)
-
- New synthetic flavone derivatives induce apoptosis of hepatocarcinoma cells
-
Natural flavonoids have broad biological activity, including anticancer. In this study, a series of novel flavone derivatives were synthesized with the substitutions of chlorine, isopropyl, methoxy, and nitro groups on the benzene ring of flavone skeleton to develop effective anticancer agents. Antiproliferative assays showed that the synthesized chemicals possess notable activity against hepatocarcinoma cells (HepG-2); in particular, the compound 6f with chlorine and dimethoxy modifications at the two benzene rings showed an IC50 at 1.1 μM to HepG-2. The 6f also displayed marked anticancer activity towards a panel of cancer cells, including nasopharyngeal carcinoma cells (CNE-2 and CNE-1), breast adenocarcinoma cell (MCF-7), and epithelial carcinoma cells (Hela). Exposing HepG-2 cells to compound 6f at 10 μM induced chromatin condensation, nuclear disassembly, and DNA fragmentation. In 6f-treated HepG-2 cells, the sub-G0 population was remarkably increased; and in these cells, both caspase-8 and caspase-9 activity was significantly increased, which in turn activated caspase-3. In addition, proapoptotic Bax was upregulated by compound 6f while the antiapoptotic Bcl-2 was downregulated. Taken together, our data suggest that the new flavonoid derivative 6f triggers apoptosis through both death-receptor and mitochondria-dependent intrinsic pathways, being a potent therapeutic agent against hepatocarcinoma.
- Liu, Huachen,Dong, Aijun,Gao, Chunmei,Tan, Chunyan,Xie, Zhenhua,Zu, Xuyu,Qu, Long,Jiang, Yuyang
-
experimental part
p. 6322 - 6328
(2010/10/03)
-
- Regioselective synthesis of 5-alkylsalicylates, 5-alkyl-2-hydroxy- acetophenones, and 5-alkyl-2-hydroxy-benzophenones by [3 + 3] cyclization of 1,3-bis(silyl enol ethers) with 2-alkyl-1,1,3,3-tetraethoxypropanes
-
(Chemical Equation Presented) A variety of 5-alkylsalicylates, 5-alkyl-2-hydroxy-acetophenones, and 5-alkyl-2-hydroxy-benzophenones was regioselectively prepared by TiCl4 mediated formal [3 + 3] cyclization of 1,3-bis(silyl enol ethers) with 2-alkyl-1,1,3,3- tetraethoxypropanes.
- Mamat, Constantin,Buettner, Stefan,Trabhardt, Tiana,Fischer, Christine,Langer, Peter
-
p. 6273 - 6275
(2008/02/10)
-
- Design and synthesis of novel RXR-selective modulators with improved pharmacological profile
-
New RXR-selective modulators possessing a 6-fluoro trienoic acid moiety (6Z olefin) or a fluorinated/heterocyclic-substituted benzene core ring, were synthesized in an expedient and selective way. A subset of these compounds was evaluated for their metabo
- Michellys, Pierre-Yves,Boehm, Marcus F.,Chen, Jyun-Hung,Grese, Timothy A.,Karanewsky, Donald S.,Leibowitz, Mark D.,Liu, Sha,Mais, Dale A.,Mapes, Christopher M.,Reifel-Miller, Anne,Ogilvie, Katheen M.,Rungta, Deepa,Thompson, Anthony W.,Tyhonas, John S.,Yumibe, Nathan,Ardecky, Robert J.
-
p. 4071 - 4075
(2007/10/03)
-
- Formylchromone derivatives as a novel class of protein tyrosine phosphatase 1B inhibitors
-
Formylchromone inhibits a human protein tyrosine phosphatase PTP1B with a IC50 value of 73 μM. The chemical reactivity of formylchromone was adjusted by substitution at various positions of the formylchromone skeleton. In an initial assessment of the structure-activity relationship, the most potent inhibitor showed an IC50 of 4.3 μM against PTP1B and strong or medium selectivity against other human PTPases, LAR and TC-PTP. This compound, however, was not selective against microbial PTPases, YPTP1 and YOP. The potency and selectivity of the formylchromone derivatives expecting further improvements provides a novel pharmacophore for the design of drugs for the treatmenrt of type 2 diabetes and obesity.
- Shim, Yi Sup,Kim, Ki Chul,Chi, Dae Yoon,Lee, Keun-Hyeung,Cho, Hyeongjin
-
p. 2561 - 2563
(2007/10/03)
-